A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma.

CONCLUSIONS: Chemotherapy plus hu14.18K322A, cytokines and NK cells is feasible and resulted in clinically meaningful responses in patients with refractory/recurrent neuroblastoma. Further studies of this approach are warranted in patients with relapsed and newly-diagnosed neuroblastoma. PMID: 28939747 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28939747?dopt=Abstract

Source: Clinical Cancer Research - September 22, 2017 Category: Cancer & Oncology Authors: Federico SM, McCarville MB, Shulkin BL, Sondel PM, Hank JA, Hutson P, Meagher M, Shafer A, Ng CY, Leung W, Janssen WE, Wu J, Mao S, Brennan RC, Santana VM, Pappo A, Furman WL Tags: Clin Cancer Res Source Type: research